Review maps peptide-drug conjugates in development for digestive system tumors

The wire

1. 01The review in Drug Design, Development and Therapy surveys peptide-drug conjugates targeting integrins, GPC3, EGFR, HER2, transferrin receptor and VEGFR in gastric, liver, pancreatic and colorectal cancer.
2. 02Conjugates are one of the more active routes for peptides as targeted oncology agents, and the piece catalogs target selection and design strategies for readers tracking the pipeline.
3. 03Evidence cited is largely preclinical with only early clinical results, so tumor-specific accumulation and reduced normal-tissue damage remain unproven in patients.

From the source

Advances of Peptide-Drug Conjugates in the Treatment of Digestive System Tumors

Drug design, development and therapy · 2026 · Yang L, An M, Ma J et al.